Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration-resistant Prostate Cancer 1

Interventions

Docetaxel 4enzalutamide 3darolutamide 3cabazitaxel 3Pluvicto 3testosterone 17 beta-cypionate 2radium Ra 223 dichloride 2Nivolumab 2sipuleucel-T 1rucaparib 1poly ICLC 1pamiparib 1lactitol 1fludarabine phosphate 1fludarabine 1fluciclovine F-18 1enfortumab vedotin 1ebastine 1copanlisib 1cabozantinib 1bempegaldesleukin 1avelumab 1alovudine 1abiraterone 1Standard of Care 1Single Photon Emission Computed Tomography Computed Tomography 1Selegiline 1Radium-223 1Radiosurgery 1Radionuclide Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Castration-resistant Prostate Cancer × PSMA-617 × Clear all
NCT07476001 2026-05-15

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
12 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡